Seres Therapeutics, Inc.
MCRBSeres Therapeutics, Inc. is a biotechnology company focused on developing microbiome-based therapeutics. The company utilizes its proprietary platform to discover, develop, and commercialize biologic products that modulate the human microbiome to treat various diseases, including those related to gastrointestinal health. Founded in 2014 and headquartered in Cambridge, Massachusetts, Seres aims to address unmet medical needs through innovative microbiome science.
Company News
Seres Therapeutics announced three presentations at the 2026 ESCMID congress highlighting Phase 1b data for SER-155, a live biotherapeutic candidate. The data demonstrated that SER-155 induced significant and durable shifts in GI microbiome composition with improved epithelial barrier integrity, correlating with reduced bloodstream infections in ...
Seres Therapeutics reported a net income of $5.7 million for full year 2025 compared to a net loss of $125.8 million in 2024, primarily driven by gains from the VOWST sale to Nestlé and reduced operating expenses. The company is prioritizing development of SER-155 for immune checkpoint-related enterocolitis and SER-603 for inflammatory bowel dis...
The human microbiome market is expected to grow from $0.85 billion in 2026 to $3.27 billion by 2035, driven by advancements in sequencing technologies, rising R&D investments, and increasing demand for personalized medicine. Currently, approximately 215 microbiome therapeutics are in development across various stages, with over 50% in clinical st...
Seres Therapeutics reported Q3 2025 earnings, highlighting progress on SER-155, a live biotherapeutic targeting bloodstream infections in stem cell transplant patients. The company secured a $3.6M CARB-X grant, reduced workforce by 25%, and is seeking additional capital to advance clinical trials.
Denodo, a leader in data management, has announced the Denodo University Challenge, 'Data and AI for Real-World Impact', which aims to encourage students to develop innovative AI-driven solutions that have a demonstrable impact on social and economic challenges. The challenge will leverage Denodo's data management and AI tools, including the Deno...
